Do analysts rate ANVS or BIVI?

Annovis Bio currently has a consensus price target of $12.00, suggesting a potential upside of 841.18%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts plainly believe Annovis Bio is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, ANVS or BIVI?

Annovis Bio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.79 N/A BioVie N/A N/A -$22.07M -$3.15 N/A

Is ANVS or BIVI more profitable?

BioVie's return on equity of -126.02% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -685.98% -258.77% BioVie N/A -126.02% -108.88%

Does the media favor ANVS or BIVI?

In the previous week, Annovis Bio had 2 more articles in the media than BioVie. MarketBeat recorded 4 mentions for Annovis Bio and 2 mentions for BioVie. BioVie's average media sentiment score of 0.09 beat Annovis Bio's score of 0.00 indicating that BioVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioVie 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BIVI or IMA?

ImageneBio has a consensus price target of $29.00, suggesting a potential upside of 495.73%. Given ImageneBio's stronger consensus rating and higher probable upside, analysts clearly believe ImageneBio is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ImageneBio 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.20

Is BIVI or IMA more profitable?

ImageneBio's return on equity of -38.99% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -126.02% -108.88% ImageneBio N/A -38.99% -34.84%

Does the media refer more to BIVI or IMA?

In the previous week, BioVie had 1 more articles in the media than ImageneBio. MarketBeat recorded 2 mentions for BioVie and 1 mentions for ImageneBio. BioVie's average media sentiment score of 0.09 beat ImageneBio's score of 0.00 indicating that BioVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BIVI or BKHA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, BIVI or BKHA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$22.07M -$3.15 N/A Black Hawk Acquisition N/A N/A N/A N/A N/A

Is BIVI or BKHA more profitable?

Black Hawk Acquisition's return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -126.02% -108.88% Black Hawk Acquisition N/A N/A N/A

Does the media refer more to BIVI or BKHA?

In the previous week, BioVie had 1 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 2 mentions for BioVie and 1 mentions for Black Hawk Acquisition. Black Hawk Acquisition's average media sentiment score of 0.35 beat BioVie's score of 0.09 indicating that Black Hawk Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Black Hawk Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BIVI or PDSB?

PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 992.37%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has preferable valuation and earnings, BIVI or PDSB?

PDS Biotechnology is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$22.07M -$3.15 N/A PDS Biotechnology N/A N/A -$34.50M -$0.64 N/A

Is BIVI or PDSB more profitable?

BioVie's return on equity of -126.02% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -126.02% -108.88% PDS Biotechnology N/A -708.18% -136.50%

Does the media refer more to BIVI or PDSB?

In the previous week, PDS Biotechnology had 3 more articles in the media than BioVie. MarketBeat recorded 5 mentions for PDS Biotechnology and 2 mentions for BioVie. BioVie's average media sentiment score of 0.09 beat PDS Biotechnology's score of -0.11 indicating that BioVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PDS Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TVGN or BIVI?

Tevogen Bio currently has a consensus target price of $100.00, suggesting a potential upside of 1,188.49%. Given Tevogen Bio's stronger consensus rating and higher probable upside, analysts plainly believe Tevogen Bio is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, TVGN or BIVI?

Tevogen Bio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tevogen Bio N/A N/A -$26.27M -$4.63 N/A BioVie N/A N/A -$22.07M -$3.15 N/A

Is TVGN or BIVI more profitable?

Tevogen Bio's return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -468.32% BioVie N/A -126.02% -108.88%

Does the media favor TVGN or BIVI?

In the previous week, BioVie had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 2 mentions for BioVie and 1 mentions for Tevogen Bio. BioVie's average media sentiment score of 0.09 beat Tevogen Bio's score of 0.00 indicating that BioVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioVie 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BioVie (BIVI) Competitors

$1.63 0.00 (0.00%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.62 0.00 (-0.31%)

As of 04:44 AM Eastern

Compare

BIVI vs. ANVS, IMA, BKHA, PDSB, and TVGN

Should you buy BioVie stock or one of its competitors? BioVie's main competitors and comparable companies include Annovis Bio (ANVS), ImageneBio (IMA), Black Hawk Acquisition (BKHA), PDS Biotechnology (PDSB), and Tevogen Bio (TVGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioVie compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and BioVie (NASDAQ:BIVI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Annovis Bio currently has a consensus price target of $12.00, suggesting a potential upside of 841.18%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts plainly believe Annovis Bio is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Annovis Bio had 2 more articles in the media than BioVie. MarketBeat recorded 4 mentions for Annovis Bio and 2 mentions for BioVie. BioVie's average media sentiment score of 0.09 beat Annovis Bio's score of 0.00 indicating that BioVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 15.9% of Annovis Bio shares are owned by company insiders. Comparatively, 0.9% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Annovis Bio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A

Annovis Bio has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, BioVie has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

BioVie's return on equity of -126.02% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
BioVie	N/A	-126.02%	-108.88%

Summary

Annovis Bio beats BioVie on 8 of the 13 factors compared between the two stocks.

How does BioVie compare to ImageneBio?

BioVie (NASDAQ:BIVI) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

4.6% of BioVie shares are held by institutional investors. Comparatively, 75.0% of ImageneBio shares are held by institutional investors. 0.9% of BioVie shares are held by company insiders. Comparatively, 2.2% of ImageneBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

BioVie has higher earnings, but lower revenue than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A
ImageneBio	$800K	69.06	-$45.35M	-$4.58	N/A

ImageneBio has a consensus price target of $29.00, suggesting a potential upside of 495.73%. Given ImageneBio's stronger consensus rating and higher probable upside, analysts clearly believe ImageneBio is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

ImageneBio's return on equity of -38.99% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-126.02%	-108.88%
ImageneBio	N/A	-38.99%	-34.84%

In the previous week, BioVie had 1 more articles in the media than ImageneBio. MarketBeat recorded 2 mentions for BioVie and 1 mentions for ImageneBio. BioVie's average media sentiment score of 0.09 beat ImageneBio's score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioVie has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Summary

ImageneBio beats BioVie on 9 of the 15 factors compared between the two stocks.

How does BioVie compare to Black Hawk Acquisition?

BioVie (NASDAQ:BIVI) and Black Hawk Acquisition (NASDAQ:BKHA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Black Hawk Acquisition's return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-126.02%	-108.88%
Black Hawk Acquisition	N/A	N/A	N/A

In the previous week, BioVie had 1 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 2 mentions for BioVie and 1 mentions for Black Hawk Acquisition. Black Hawk Acquisition's average media sentiment score of 0.35 beat BioVie's score of 0.09 indicating that Black Hawk Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Black Hawk Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioVie has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Black Hawk Acquisition has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market.

4.6% of BioVie shares are held by institutional investors. 0.9% of BioVie shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

BioVie beats Black Hawk Acquisition on 4 of the 7 factors compared between the two stocks.

How does BioVie compare to PDS Biotechnology?

BioVie (NASDAQ:BIVI) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

BioVie has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

BioVie's return on equity of -126.02% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-126.02%	-108.88%
PDS Biotechnology	N/A	-708.18%	-136.50%

PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 992.37%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, PDS Biotechnology had 3 more articles in the media than BioVie. MarketBeat recorded 5 mentions for PDS Biotechnology and 2 mentions for BioVie. BioVie's average media sentiment score of 0.09 beat PDS Biotechnology's score of -0.11 indicating that BioVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PDS Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

PDS Biotechnology is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A

4.6% of BioVie shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 0.9% of BioVie shares are held by company insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

PDS Biotechnology beats BioVie on 8 of the 13 factors compared between the two stocks.

How does BioVie compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and BioVie (NASDAQ:BIVI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Tevogen Bio's return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-468.32%
BioVie	N/A	-126.02%	-108.88%

4.6% of BioVie shares are owned by institutional investors. 65.6% of Tevogen Bio shares are owned by company insiders. Comparatively, 0.9% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tevogen Bio has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, BioVie has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

In the previous week, BioVie had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 2 mentions for BioVie and 1 mentions for Tevogen Bio. BioVie's average media sentiment score of 0.09 beat Tevogen Bio's score of 0.00 indicating that BioVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tevogen Bio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A

Tevogen Bio currently has a consensus target price of $100.00, suggesting a potential upside of 1,188.49%. Given Tevogen Bio's stronger consensus rating and higher probable upside, analysts plainly believe Tevogen Bio is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BioVie beats Tevogen Bio on 8 of the 12 factors compared between the two stocks.

Get BioVie News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIVI vs. The Competition

Export

Metric	BioVie	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.78M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.52	13.88	274.08	25.69
Price / Sales	N/A	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	1.20	15.40	10.47	6.32
Net Income	-$22.07M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-8.43%	-1.70%	-0.67%	0.17%
1 Month Performance	-23.83%	-6.17%	-3.17%	-3.27%
1 Year Performance	-12.37%	30.67%	15.14%	5.58%

BioVie Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIVI BioVie	1.0138 of 5 stars	$1.63 flat	N/A	-11.4%	$13.78M	N/A	N/A	13
ANVS Annovis Bio	1.8489 of 5 stars	$1.29 +8.0%	$12.00 +833.9%	-42.7%	$54.84M	N/A	N/A	7	News Coverage Gap Up
IMA ImageneBio	2.6502 of 5 stars	$4.77 -0.8%	$29.00 +508.0%	-38.8%	$54.14M	$800K	N/A	18	Gap Up
BKHA Black Hawk Acquisition	N/A	$12.15 +1.3%	N/A	+9.0%	$50.40M	N/A	N/A	N/A	High Trading Volume
PDSB PDS Biotechnology	2.4142 of 5 stars	$0.88 +5.0%	$9.00 +918.1%	-21.5%	$49.48M	N/A	N/A	21	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIVI) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioVie (BIVI) Competitors